Details of the Drug Reposition

General Information of This Drug (ID: DM0BL2G)

• Drug Name: Mitiperstat (DM0BL2G)
• Synonyms: Mitiperstat; AZD4831; Mitiperstat [INN]; AZD-4831; S6GYK3X4QQ; 1933460-19-5; UNII-S6GYK3X4QQ; AZD-4831 [WHO-DD]; 1-((2-((1R)-1-Aminoethyl)-4-chloro-phenyl)methyl)-2-thioxo-5hpyrrolo(3,2-d)pyrimidin-4-one; 4H-Pyrrolo(3,2-d)pyrimidin-4-one, 1-((2-((1R)-1-aminoethyl)-4-chlorophenyl)methyl)-1,2,3,5-tetrahydro-2-thioxo-; 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-1,2,3,5-tetrahydro-2-thioxo-; Alternative Preparation; MITIPERSTAT [USAN]; Azd 4831; CHEMBL5095218; SCHEMBL17782047; GTPL12154; AZD 4831 [WHO-DD]; BHKKSKOHRFHHIN-MRVPVSSYSA-N; BDBM312172; GLXC-26157; EX-A7129; compound 16 [PMID: 36005476]; HY-145581; CS-0376445; US9616063, 3; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one; 1-({2-[(1R)-1-aminoethyl]-4-chlorophenyl}methyl)-2-sulfanylidene-1H,2H,3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one; 1-{2-[(1R)-1-Aminoethyl]-4-chlorobenzyl}-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one
• Drug Type: Small molecule

Information on Drug Reposition of This Drug

1 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Heart failure with preserved ejection fraction	DISESK0U	BD11.0	Phase 2/3	[1]

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chronic obstructive pulmonary disease	DISQCIRF	CA22	Phase 2	[2]

References

• [1] ClinicalTrials.gov (NCT04986202) A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05492877) A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.